380 related articles for article (PubMed ID: 17383573)
21. Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats.
Tsao HH; Lin KJ; Juang JH; Skovronsky DM; Yen TC; Wey SP; Kung MP
Nucl Med Biol; 2010 May; 37(4):413-9. PubMed ID: 20447551
[TBL] [Abstract][Full Text] [Related]
22. A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2.
Huang ZR; Tsai CL; Huang YY; Shiue CY; Tzen KY; Yen RF; Hsin LW
PLoS One; 2016; 11(9):e0161295. PubMed ID: 27612194
[TBL] [Abstract][Full Text] [Related]
23. Derivatization of (±) dihydrotetrabenazine for copper-64 labeling towards long-lived radiotracers for PET imaging of the vesicular monoamine transporter 2.
Kumar A; Lo ST; Öz OK; Sun X
Bioorg Med Chem Lett; 2014 Dec; 24(24):5663-5665. PubMed ID: 25467156
[TBL] [Abstract][Full Text] [Related]
24. Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas.
Fagerholm V; Mikkola KK; Ishizu T; Arponen E; Kauhanen S; Någren K; Solin O; Nuutila P; Haaparanta M
J Nucl Med; 2010 Sep; 51(9):1439-46. PubMed ID: 20720057
[TBL] [Abstract][Full Text] [Related]
25. [
Weng CC; Huang SL; Chen ZA; Lin KJ; Hsiao IT; Yen TC; Kung MP; Wey SP; Hsu CH
Ann Nucl Med; 2017 Aug; 31(7):506-513. PubMed ID: 28451991
[TBL] [Abstract][Full Text] [Related]
26. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine.
Koeppe RA; Frey KA; Kuhl DE; Kilbourn MR
J Cereb Blood Flow Metab; 1999 Dec; 19(12):1376-84. PubMed ID: 10598942
[TBL] [Abstract][Full Text] [Related]
27. Study of Vesicular Monoamine Transporter 2 in Myopic Retina Using [
Sun Y; Zhao N; Liu W; Liu M; Ju Z; Li J; Cheng Z; Liu X
Mol Imaging Biol; 2018 Oct; 20(5):771-779. PubMed ID: 29520623
[TBL] [Abstract][Full Text] [Related]
28. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
Lin SC; Lin KJ; Hsiao IT; Hsieh CJ; Lin WY; Lu CS; Wey SP; Yen TC; Kung MP; Weng YH
J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
[TBL] [Abstract][Full Text] [Related]
29. Molar activity of [
Liu C; Tang J; Xu Y; Cao S; Fang Y; Zhao C; Chen Z
J Pharm Biomed Anal; 2021 Sep; 203():114212. PubMed ID: 34153939
[TBL] [Abstract][Full Text] [Related]
30. In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass.
Eriksson O; Jahan M; Johnström P; Korsgren O; Sundin A; Halldin C; Johansson L
Nucl Med Biol; 2010 Apr; 37(3):357-63. PubMed ID: 20346875
[TBL] [Abstract][Full Text] [Related]
31. Imaging of VMAT2 binding sites in the brain by (18)F-AV-133: the effect of a pseudo-carrier.
Zhu L; Qiao H; Lieberman BP; Wu J; Liu Y; Pan Z; Ploessl K; Choi SR; Chan P; Kung HF
Nucl Med Biol; 2012 Oct; 39(7):897-904. PubMed ID: 22749185
[TBL] [Abstract][Full Text] [Related]
32. Brain uptake of a non-radioactive pseudo-carrier and its effect on the biodistribution of [(18)F]AV-133 in mouse brain.
Wu X; Zhou X; Zhang S; Zhang Y; Deng A; Han J; Zhu L; Kung HF; Qiao J
Nucl Med Biol; 2015 Jul; 42(7):630-6. PubMed ID: 25910857
[TBL] [Abstract][Full Text] [Related]
33. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT
Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of 2-amino-dihydrotetrabenzine derivatives as probes for imaging vesicular monoamine transporter-2.
Zhu L; Liu J; Kung HF
Bioorg Med Chem Lett; 2009 Sep; 19(17):5026-8. PubMed ID: 19632829
[TBL] [Abstract][Full Text] [Related]
35. In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.
Wang JL; Oya S; Parhi AK; Lieberman BP; Ploessl K; Hou C; Kung HF
Nucl Med Biol; 2010 May; 37(4):479-86. PubMed ID: 20447560
[TBL] [Abstract][Full Text] [Related]
36. Mapping the target localization and biodistribution of non-radiolabeled VMAT2 ligands in rat brain.
Deng A; Wu X; Zhou X; Zhang Y; Yin W; Qiao J; Zhu L
AAPS J; 2014 May; 16(3):592-9. PubMed ID: 24706374
[TBL] [Abstract][Full Text] [Related]
37. In vitro binding affinity vs. in vivo site occupancy: A PET study of four diastereomers of dihydrotetrabenazine (DTBZ) in monkey brain.
Kilbourn MR; Cole EL; Scott PJH
Nucl Med Biol; 2021 Jan; 92():38-42. PubMed ID: 32122751
[TBL] [Abstract][Full Text] [Related]
38. PET Imaging of VMAT2 with the Novel Radioligand [
Nag S; Jahan M; Tóth M; Nakao R; Varrone A; Halldin C
ACS Chem Neurosci; 2021 Dec; 12(24):4580-4586. PubMed ID: 34813272
[TBL] [Abstract][Full Text] [Related]
39. Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent.
Lin KJ; Weng YH; Wey SP; Hsiao IT; Lu CS; Skovronsky D; Chang HP; Kung MP; Yen TC
J Nucl Med; 2010 Sep; 51(9):1480-5. PubMed ID: 20720042
[TBL] [Abstract][Full Text] [Related]
40. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
